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ABSTRACT 
 
 
High-throughput metabolomics investigations, when conducted in large human cohorts, represent 
a potentially powerful tool for elucidating the biochemical diversity underlying human health and 
disease. Large-scale metabolomics data sources, generated using either targeted and untargeted 
platforms, are becoming more common. Appropriate statistical analysis of these complex high-
dimensional data will be critical for extracting meaningful results from such large-scale human 
metabolomics studies. Therefore, we consider the statistical analytical approaches that have been 
employed in prior human metabolomics studies. Based on the lessons learned and collective 
experience to date in the field, we offer a step-by-step framework for pursuing statistical analyses 
of human metabolomics data. We discuss the range of options and potential approaches that may 
be employed at each stage of data management, analysis, and interpretation and offer guidance 
on the analytical decisions that need to be considered over the course of implementing an analysis 
workflow. Certain pervasive analytical challenges facing the field warrant ongoing focused 
research. Addressing these challenges, particularly those related to analyzing human 
metabolomics data, will allow for more standardization of as well as advances in how research in 
the field is practiced. In turn, such major analytical advances will lead to substantial improvements 
in the overall contributions of human metabolomics investigations.  
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Introduction 
Rapid advancements in mass spectrometry (MS) technologies have enabled the generation of 
large-scale metabolomics data in human studies. These technical advances have outpaced the 
development of statistical methods for handling and analyzing datasets of now burgeoning size 
and complexity.1-3 Early investigations using metabolomics technologies have applied a variety of 
statistical methods in analyses of datasets containing up to 200 metabolite measures, typically 
acquired from a targeted metabolomics platform collected from human studies involving tens to 
hundreds of observations. Available untargeted metabolomics platforms now allow the 
measurement of thousands of metabolite variables, most which are unknown molecular species 
that demonstrate varying levels of intercorrelations within a given dataset as well as correlations 
with a given clinical outcome. Furthermore, current metabolomics technologies have augmented 
throughput capacity that can facilitate data collection for thousands of observations per human 
cohort experiment. At present, however, there are no existing standard protocols for analyzing 
these increasingly complex metabolomics data. Thus, herein, we review the available statistical 
methods for analyzing high-dimensional metabolomics data in the setting of a clinical study. We 
also outline an accessible yet flexible approach that can be used to optimize sensitivity and 
specificity for identifying potentially important metabolites associated with a clinically relevant 
outcome. 
 
Analytical Challenges 
Due to the increasing complexity of metabolomics data, combined with the variety of different 
study designs employed in practice, customized approaches are often required for analyzing 
metabolite variation in relation to clinical outcomes. Notwithstanding differences in study design 
and data structure, common to almost all metabolomics datasets is the need to address certain 
statistical considerations (Table 1). An initial key consideration is missingness, given that all 
metabolomic data invariably demonstrate patterns of missing values that are often but not always 
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more frequent for low abundant metabolites. Contributing factors include underlying biology (e.g., 
very low or true zero values due to biological differences between healthy and disease-enriched 
cohorts) and technical issues (e.g., actual values below the detection limits for a given method, 
which may or may not be rectified using different or complementary methods). The etiology of 
missing values will vary, at least in part, based on the platform used to profile metabolites (i.e. 
NMR, GC-MS, LC-MS). In rare circumstances, for certain types of metabolites (e.g., derivatives 
of known toxic exposures), missing values may be most appropriately coded as true zero values 
as opposed to imputed. For non-zero metabolite variables, transformation is usually 
recommended due to frequently right-skewed distributions. Irrespective of distribution patterns, 
metabolite variables always demonstrate intercorrelations. Importantly, the extent to which 
intercorrelations exist between metabolites will vary substantially between datasets due to a 
variety of factors, including those related to study sampling as well as technical issues. 
Furthermore, even within a given study sample, metabolite variation will be influenced by time-
dependent factors given that a portion of the human metabolome changes dynamically in 
response to acute perturbation or stress while another portion of the metabolome exhibits 
relatively little change over time, except in response to major chronic exposures. 
 
Statistical Methods for Analyzing Metabolomics Data 
A variety of different statistical methods are available for analyzing high-dimensional 
metabolomics data. Methods that have been applied in prior or ongoing clinical metabolomics 
studies are summarized in Table 2 and are also described in more detail herein. 
 
Univariate analyses with multiple testing correction, such as the Bonferroni correction for 
controlling the global type I error rate or the Benjamini-Hochberg correction for controlling the 
false discovery rate (FDR),1 have previously been applied in a variety of predominantly targeted 
metabolomics studies.2-4 This approach involves M tests, where M is the total number of 
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metabolite variables analyzed separately in relation to an outcome of interest. The P value for 
each separate metabolite test can be considered significant or non-significant based on a P value 
threshold that is corrected to account for the fact that multiple hypotheses have are being tested. 
The Bonferroni method is commonly used and deems a metabolite significant if it is smaller than 
0.05/M, while other corrections can be used to control the false discovery rate. Overall, univariate 
analysis with multiple testing correction is an attractive approach because it is simple to implement 
and provides a measure of statistical significance for each covariate that is easy to interpret. 
However, this approach alone does not account for associations between metabolites and 
conditional associations. For instance, a given metabolite may appear significantly associated 
with an outcome in isolation but does not demonstrate a significant association when other 
metabolite associations are taken into account. Furthermore, approaches to account for multiple 
testing, such as the Bonferroni correction or even FDR, are considered conservative in the setting 
of a large number of analyzed metabolites, leading to limited statistical power overall. 
 
The principle components analysis (PCA) approach5 is designed to reduce the dimension of the 
number of metabolites being analyzed, assuming there is substantial correlation between 
metabolites in a given dataset. Thus, PCA directly addresses the issue of intercorrelatedness and 
has been used in prior human metabolomics studies, usually in combination with other methods. 
The PCA approach takes the original metabolite factors and finds linear combinations of these 
factors that are orthogonal to each other and that explain the most variation in the metabolite 
dataset. The PCA approach can be used to identify factor combinations associated with a given 
outcome, but PCA is not intrinsically designed to identify original predictor variables (i.e., 
metabolites) of importance. A varimax rotation can be used to increase the interpretability of 
principal components, given that principal components are comprised of a small subset of the 
original metabolites.6 Those metabolites contributing to a given principal component can be 
ranked by the importance of their contributions. However, for each contributing metabolite, a 
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measure of the magnitude of its association with given outcome is not provided, and a test of the 
significance of association is also not provided. 
 
The partial least squares (PLS) regression method7 aims to maximize the covariance between a 
matrix of metabolites and a continuous outcome (or categorical outcome using the PLS 
discriminant analysis [DA] variation8) by decomposing metabolite and outcomes data into latent 
structures. This approach aims to maximize the covariance between the outcome and matrix of 
metabolites by projecting both to linear subspaces of the original variables. While finding reduced 
dimensions that can explain the outcome variable, PLS regression generally only provides a 
measure of variable importance and does not naturally perform variable selection, though a 
number of ad hoc approaches for variable selection have been proposed.9,10 Nonetheless, no 
clear-cut approach is best for determining which metabolites are actually important in predicting 
the outcome. Sparse extensions of both approaches have been proposed,11-15 which add a 
penalty to the loading scores forcing some of the variables to have zero weight in the final model. 
One can take the list of non-zero metabolites to be the metabolites that are deemed important. 
This is potentially a very fruitful direction for identifying important metabolites. 
 
The linear discriminant analysis (LDA) approach aims to find linear combinations of metabolite 
variables that are best able to separate classes of a categorical outcome. Although LDA cannot 
be used for a continuous outcome, such an outcome may be discretized for LDA application. 
Conventionally, LDA will perform poorly or can even fail completely when the number of 
covariates exceeds the number of subjects,16,17 a common feature of metabolomics datasets. 
Furthermore, the LDA approach does not intrinsically identify a set of important variables and can 
only be used to create variable rankings or importance measures. For this reason, we consider a 
sparse version of LDA,18-20 which again adds a penalty for the variable loadings and, thus, allows 
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for simultaneous variable selection. As with PCA and PLS, LDA can provide a measure of variable 
importance that can be used for metabolite ranking. 
 
The least absolute shrinkage and selection operator (LASSO) approach aims to fit a model that 
regresses the outcome against all of the metabolites simultaneously and applies a penalty to the 
magnitude of regression coefficients to achieve sparse variable selection.21 Generally, regression 
models are extremely noisy, if not infeasible, when the number of metabolites is large. LASSO 
applies a penalty to the magnitude of the regression coefficients, which forces the regression 
coefficients for many coefficients to be zero while also shrinking others in magnitude. LASSO is 
useful in both prediction and metabolite selection. One can take the collection of metabolites with 
non-zero regression coefficients from LASSO to be "significant" in the sense that they are 
associated with the outcome. This should not be confused with statistical significance in the 
general sense of p-values and rejecting null hypotheses; however, it is a powerful tool for variable 
selection. To perform LASSO, one must also select a tuning parameter for the penalty; however, 
this is easily done via cross validation and is implemented in statistical software. LASSO has 
many desirable large sample properties including model selection consistency, which states that 
one can select the proper metabolites with probability tending toward 1 if we have enough data. 
LASSO is known, however, to struggle in small samples with highly correlated covariates as it will 
simply choose one among the group of correlated variables and force the others to be zero. In 
these cases, related methods such as elastic net, which is a compromise between the LASSO 
and ridge regression procedures, can be utilized as well. LASSO and its variants can be 
implemented in the glmnet package in R.22 
 
Random forest is a non-parametric ensemble method that prioritizes prediction by attempting to 
find non-linear patterns in metabolites that can explain variation in a given outcome.23 Random 
forests are very powerful tools if the relationships between the metabolites and the outcome are 
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complex and non-linear. One drawback of this approach is that, similar to PCA, it does not provide 
a measure of statistical significance or provide any p-value or equivalent quantity. Metabolite 
importance, however, can be assessed by removing metabolites one at a time, re-running the 
procedure, and seeing how much predictive capability was lost. This provides the analyst with a 
list ranking the most important metabolites but does not provide a cutoff for which metabolites are 
significant. Random forests can be implemented in either the randomForest or h2O packages in 
R.24,25 
 
Additionally, there is a vast array of methods in the machine learning literature that provide very 
flexible models for handling data with a large number of covariates. These approaches are 
appreciably powerful tools for predicting a given outcome of interest although, in many cases, at 
the expense of interpretability of resulting models. Examples of commonly used approaches 
include support vector machines (SVM), neural networks, and the previously mentioned random 
forests.26,27 All of these methods are subject to many of the same limitations, as discussed for 
random forests, in that they can provide a variable importance measure but do not provide a set 
of variables that can be thought of as statistically significant. 
 
A note regarding sparsity in statistical methods is warranted. A general problem of many 
approaches that may be used to analyze metabolomics data is that they do not easily result in a 
final list of "top hit" metabolites associated with a given outcome of interest. Instead, they are 
useful for providing heuristic measures that indicate variable importance and, in doing so, do not 
eliminate clinical or other covariates from the model of total covariates included in analyses. For 
this reason, we recommend focusing on sparse alternatives to statistical methods because, as 
discussed above, they are intended to directly address this issue. In this context, sparsity is based 
on the assumption that the number of true positives is limited, such that the contribution to 
variation in an outcome can be defined by a set number of non-zero values for a set number of 
9 
 
coefficients, with the remaining being zero values. One of the naivest ways to achieve a sparse 
result, for instance, would be a stepwise (e.g., forward) selection, but alternate methods are 
preferred when the number of metabolites is far in excess to the number of observations. 
 
Metabolomics Analysis Workflow 
In addition to considering which statistical methods to apply in relating curated metabolomics data 
to clinical outcomes, a series of study design and data management steps are required as part of 
a complete analytical workflow. While not intended to be comprehensive, an overview of these 
steps is provided below. 
 
Step 1: Study Design 
Prior to beginning any experiment, all aspects of study design should be carefully determined. 
This process includes a decision on whether metabolite predictors of a given outcome will be 
investigated in a case-control (and, if so, the number of cases and controls), a case-cohort, or 
total cohort design. In this step, it is critically important to consider the number of outcome 
occurrences (i.e., cases) available for analysis and the anticipated effect size for metabolomic 
variation in relation to case status. Also, it is necessary to decide on whether the metabolomics 
profiling method to be used will be untargeted or targeted and, if targeted, the type of targeted 
approach. This decision will determine the approximate number of metabolites that will be 
measured. Taken together, information on the total number of observations, number of cases, 
and number of metabolites measured will determine the extent to which the experiment will be 
adequately powered for detecting clinically significant associations of interest. Similar 
considerations are needed for analysis of continuous as opposed to binary outcomes. Overall, 
this step is essential for conducting analysis of metabolomics data wherein the number of 
metabolites measurable typically far exceeds the number of individuals studied within a given 
experiment. 
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Step 2: Data Management 
It is becoming increasingly recognized that several key data management steps are extremely 
important for ensuring not only the integrity but also feasibility of metabolomics data analysis. For 
instance, it is always important to perform a careful assessment for batch-to-batch variability that 
can often persist even after preprocessing steps have been successfully completed (e.g., for 
alignment of mass spectral features).28 Accordingly, an informed decision is possible regarding 
whether normalization of data to internal standards or to pooled plasma measures is needed.29-31  
 
All datasets should be examined for their data structure, including the distribution and type of 
missingness across metabolites and across individuals. Different approaches to handling 
missingness may be suitable depending on the types of metabolites profiled (e.g., known to be 
rare, low abundant, or technically difficult to detect). Investigators have imputed values that are a 
fraction (e.g. 0.5) the lowest value measured for a given analyte, based on the assumption that 
most missingness for a given platform is due to limits of detection. Other imputation methods are 
possible, including replacement of all missing values with zero. Analytes with a large proportion 
of measures missing may also be treated as dichotomous variables (non-missing versus missing), 
subset analyses are always possible, and some investigators have elected to exclude analytes 
with substantial missingness from all analyses. All approaches to handling missing values may 
introduce bias, depending on the method and cohort characteristics; a deeper examination of the 
relative merits of each approach is a subject of ongoing research (e.g. sensitivity analyses 
performed with and without variables potentially requiring imputation). After having issues related 
to missingness addressed, metabolite variables typically benefit from applying transformation and 
scaling to allow for appropriateness and comparability of statistical analyses (Figure 1). Although 
natural log transformation is commonly used for most or all metabolite variables in a given dataset, 
given the typical high proportion of metabolites with right-skewed distribution, this approach may 
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not be optimal for all variables.32 We recommend performing a natural log transformation of all 
metabolite variables and assessing the skewness before and after transformation. For those 
metabolites for which the skewness is not improved after transformation, we recommend retaining 
the original untransformed variables for further analysis, with transformed values used for the 
other metabolites. While standardization of transformed variables is also commonly used, so that 
magnitudes of effect are comparable across models, other approaches such as Pareto or level 
scaling may be more appropriate for certain study designs (i.e. taking into consideration the main 
research questions and outcomes of interest).32 
 
Step 3: Optional Simulation Analyses 
If feasible, an ideal approach is to develop a dataset that simulates design and size of the study 
at hand, including the number of metabolites measured and the expected or known number of 
outcomes. Simulated data allow for comparisons of performance of the different statistical 
analysis methods, so that the most optimal method can be selected for a given study. Simulations 
can be particularly useful for guiding the design of studies that are in the early planning phases, 
particularly those for which the number of metabolites and the number of study subjects has yet 
to be determined. To perform simulations that replicate a given study, some features of the data 
must be known. For instance, if prior data is already available, the empirical distribution of the 
metabolites can be used for simulation (Figure 2). One can resample the rows of the true data to 
obtain simulated data that closely replicate the true data, and then an outcome can be generated 
assuming a pre-specified relationship with the metabolites. Another possibility is to learn the 
covariance matrix among all the metabolites in the study and then draw values from a multivariate 
normal distribution with this covariance to create simulated metabolite variables. If an example of 
true data is not available and simulations are being used to design a new study, then a dataset 
from previously conducted related study may be used to guide the simulation design. With 
simulated datasets in hand, it is possible to obtain power calculations that are relevant and 
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applicable for planning study design. One can simulate metabolites and an outcome and repeat 
this process many times over while recording the percentage of times a metabolite marker of 
interest is identified, which provides the power at the given sample size. This process can be 
performed iteratively with a number of different sample sizes, and different pre-specified 
associations between the metabolites and outcome, to gain a better understanding of the power 
available to identify signals in the planned study.  
 
Step 4: Cross-Sectional or Prospective Analyses (i.e., Outcomes Analyses) 
After selecting the most appropriate statistical approach, based on prior experience or the results 
of simulation analyses (Step 3 above), applying a method that includes internal cross-validation 
needs to be considered. Cross-validation procedures are intended to optimize generalizability and 
reduce variability of results by performing repeated analyses on different partitions of the dataset 
and then averaging the results to estimate a final model. For instance, in k-fold cross-validation, 
the total dataset is randomly divided into k equally sized subsets, and k-1 subsets are analyzed 
while reserving a different single subset for validation during each iteration. An alternative to 
cross-validation is conventional validation or dividing the original dataset into training and 
validation subsets (e.g., 2/3, 1/3) while assuming the original dataset size is large enough to 
accommodate this approach and a separate validation cohort is not available. Yet another option 
for assessing generalizability is to apply other statistical methods and compare results,33 as an 
investigator can feel more confident about results that are consistently obtained irrespective of 
the statistical technique used (Figure 3). 
 
Step 5: Visualization of Main Findings 
There are many different approaches to visualizing metabolomics data as part of the workflow for 
understanding the structure of a dataset as well as interpreting and communicating results of 
relational analyses. Many approaches are borrowed from other established fields. Common 
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visualization types include Manhattan plots, volcano plots, and heatmaps, each of which offer 
complementary information with respect to conveying information about the significance or effect 
size of associations between multiple metabolites and one or more outcomes of interest (Figure 
4). Because the number of metabolites analyzed in relation to a given clinical trait or outcome 
may be quite large, visualization methods that include clustering on inter-metabolite associations 
may be additionally informative.34 Visualizations that can provide information about network 
relationships, particularly when combined with knowledge about putative metabolic pathways,34 
may also be relevant depending on the types of metabolites measured. For untargeted 
metabolomics studies, network analyses based on known or previously reported putative 
biological relationships will be limited based on the extent to which most newly discovered 
analytes of interest will novel (i.e. of previously unknown identity). 
 
Step 6: Prioritization of Results for Follow-Up Investigations 
When using an untargeted MS method, the majority of significantly associated metabolites will 
invariably be novel (i.e., previously unidentified molecular species). Thus, an imperative next step 
in the scientific process is to identify such novel molecules of potential clinical importance. 
However, the process of identifying the specific chemical structure of a previously unknown small 
molecule is time-consuming and potentially very resource-intensive, depending on the molecule’s 
relative abundance in available biospecimens and other characteristic features. Therefore, the 
results of statistical analyses should ideally be robust and convincing before they are used to 
direct efforts made towards novel small molecule identification. To this end, several statistical 
approaches to prioritizing small molecules for follow-up identification are possible. Beyond cross-
validation or conventional validation within a dataset, external replication in a separate cohort is 
ideal – and even further value can be gained from using different metabolomics platforms.35 In 
addition, confirmatory results from performing different types of statistical analyses (e.g., 
traditional and non-traditional) in both training and validation cohorts may be informative. 
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Conclusions 
High-throughput metabolomics data provide an exciting area of research for scientific discovery, 
but are accompanied by a number of statistical challenges that must be properly addressed to 
infer meaningful results from these complex data. Herein, we have reviewed and outlined practical 
solutions for many of the common problems found in metabolomics data analysis. While outlining 
some guidelines for future researchers on how to address these issues, the optimal solution at 
any given stage of data management and analysis depends on the size and design of the specific 
data and study at hand. Thus, a critical aspect of any analysis is explicit recognition of the 
strengths and weaknesses of the selected approaches as well as a complete understanding of 
the assumptions that go into each decision that is made throughout the analysis workflow. Many 
important decisions, such as handling missing data and transforming right-skewed data, can have 
meaningful impacts on the final analysis results. Therefore, we recommend that researchers 
perform sensitivity analyses with respect to these decisions to assess the robustness of their 
results to such subjective choices. In addition, any findings from primary analyses should be 
replicated in additional studies to confirm their potential to serve as meaningful scientific findings, 
irrespective of the statistical decisions made. 
 
While we have reviewed potential solutions for the problems that are often encountered in human 
metabolomics studies, many of these issues do not have definitive answers, and this presents 
possibilities for future methods research that can aim to improve decision making at each stage 
of the analysis workflow. Certain pervasive challenges, such as how to best handle missing data, 
may be addressed using a number of possible approaches although most of these approaches 
are ad hoc and often favored due to their ease of application. The same can be said for the 
transformation of variables as well as how to address batch-to-batch variability across a large 
cohort-wide experiment. These are all open areas of research, and finding optimal solutions will 
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lead to substantial improvements in the analysis, reproducibility, and overall contributions in the 
field of human metabolomics investigation. 
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Table 1. Statistical Considerations for Human Metabolomics Data 
 
Consideration Notes and Examples 
Missingness • Patterns of missing values tend to be non-random and are even 
sometimes predictable. For example, missing values may often but 
not always be more frequent for metabolites that are intrinsically low 
in abundance when measured from a given tissue type. 
• Missingness may be due to biological and/or technical reasons. 
Data distributions • Many but not all metabolites tend to demonstrate right-skewed 
distributions in most types of human studies (e.g., healthy controls 
or disease-specific referral samples). 
• Certain metabolites will display a substantial proportion of zero 
values that may be considered true zero values based on biology 
(an issue to be considered along with but distinguished from 
missingness). 
Intercorrelations • Intercorrelations between metabolites may well reflect clustering of 
small molecules by known or (mostly) unknown biological pathways. 
• Intercorrelations will vary widely depending on a given exposure or 
background, chronic disease status, and other yet unidentified 
factors. 
• Intercorrelations will also vary depending on the underlying MS 
method used to create a given dataset (i.e., untargeted vs. targeted, 
and the specific technical methods used). 
Time-dependence • Whereas a portion of the human metabolome changes dynamically 
in response to acute perturbation or stress, many other metabolites 
display variation only over several days to weeks in response to 
subacute perturbations; other portions of the metabolome may yet 
exhibit relatively little change over time, except in response to major 
chronic exposures. 
Confounding factors • Metabolite values will vary in response to factors that are 
measurable as well as factors that are not easily measurable for a 
given study, such as acute and chronic dietary patterns, microbiota, 
and environmental exposures. 
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Table 2. Statistical Analysis Methods for Outcomes Analyses of Human Metabolomics Data 
Method Univariate or 
Multivariate 
Handling 
binary 
outcome 
Handling 
continuous 
outcome 
P value for 
significant 
metabolites 
Metabolite 
selection 
Advantages Disadvantages 
Multiple tests (e.g., 
univariate linear 
regression) with 
Bonferroni correction 
Univariate Yes Yes Yes Yes Simple, easy 
to use and 
interpret 
results 
Very conservative 
and does not 
account for 
intercorrelation 
Multiple tests with 
false discovery rate 
(FDR) 
Univariate Yes Yes Yes Yes Simple, easy 
to use, less 
conservative 
than 
Bonferroni 
correction 
 
Principal component 
analysis (PCA) 
Multivariate Yes Yes No No Effective for 
variable 
reduction 
No intrinsic clarity 
on how to select 
or rank variables 
Sparse partial least 
squares (SPLS) 
Multivariate No Yes No Yes   
Linear discriminant 
analysis (LDA) 
 Yes No No Yes   
Random forests and 
other machine 
learning approaches 
Multivariate Yes Yes No No Can find 
complex 
relationships 
between 
variables 
If data is truly 
linear, this will be 
less efficient 
Least absolute 
shrinkage and 
selection operator 
(LASSO) 
Multivariate Yes Yes No Yes   
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Figure 1. Metabolite data transformation and centering. A frequently used approach for managing metabolite data collected in a 
large human cohort study involves log transforming each metabolite measures and centering the data on plate median to account for 
batch to batch variation. 
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Figure 2. Actual and simulated metabolomics data. Previously analyzed data, or prior detailed knowledge of the structure of 
metabolomics data collected from an existing human cohort study (Panel A) can be used to construct simulated data that mimics the 
data structure observed from real measures (Panel B). These simulated data can be used to estimate statistical power, based on one 
or more methods of analyses, for planning the design of a future study. 
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Figure 3. Using multiple statistical methods to evaluate results. When relating a panel of metabolites to a given outcome, 
multiple different statistical methods can be used with the results compared. Although conventional and machine learning models 
tend to agree on the top ranked metabolite associations with a given outcome, more divergent and potentially complementary 
information is offered by the second and third tier metabolite associations. Discordant results likely reflect different assumptions and 
features between methods, such as the assumption of linearity of association between a predictor and outcome for conventional 
regression models. FDR, false discovery rate; LASSO, least absolute shrinkage and selection operator; RF, random forests; MCFS, 
monte carlo feature selection; RKNN, random K nearest neighbors. 
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Figure 4. Visualizing results. Different approaches to visualizing the results of relating multiple metabolites with multiple clinical 
outcomes in a large human metabolomics study are possible, including but not limited to combined Manhattan plots (Panel A) and a 
paired heatmap depicting values for both beta coefficients and P values (Panel B). 
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